CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CRISPR Therapeutics (CRSP) PT Lowered to $59 at Barclays
August 6, 2024 3:02 AM EDTBarclays analyst Gena Wang lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $59.00 (from $67.00) while maintaining a Equalweight rating.... More
CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c
August 5, 2024 4:04 PM EDTCRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
... MoreRodman & Renshaw Starts CRISPR Therapeutics (CRSP) at Buy
August 2, 2024 6:44 AM EDTRodman & Renshaw analyst Tony Butler initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $90.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $54.85 yesterday.
... More